RBL 001/RBL 002/RBL 003/RBL 004Alternative Names: Lipo-MERIT; RB 0003; RB_0003; RBL001.1/RBL002.2/RBL003.1/RBL004.1; RBL001/RBL002/RBL003/RBL004; RNA-LPX; Tetravalent RNA-lipoplex Cancer Vaccine
Latest Information Update: 20 Apr 2015
At a glance
- Originator BioNTech
- Class Cancer vaccines; RNA vaccines; Synthetic vaccines
- Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Malignant melanoma
Most Recent Events
- 01 Mar 2015 Phase-I clinical trials in Malignant melanoma in Germany (IV) (NCT02410733)